Biocon’s $3.3bn Biosimilars Big Leap Also Marks Viatris’ 'Smart' Exit, Albeit Toehold

 
• By Anju Ghangurde
  
Kiran Mazumdar Shaw
Biocon chief Kiran Mazumdar-Shaw

More from Business

More from Scrip